ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Odonate Therapeutics Inc

Odonate Therapeutics Inc (ODT)

1.12
0.00
(0.00%)
Al cierre: 23 Diciembre 3:00PM
1.12
0.00
( 0.00% )
Fuera de horario: -

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
1.12
Postura de Compra
1.11
Postura de Venta
1.16
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
Precio Anterior
1.12
Precio de Apertura
-
Hora
Última hora de negociación
-
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
-
Acciones en circulación
14,626,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
2.24
Beneficio por acción (BPA)
0.5
turnover
-
Beneficio neto
7.33M

Acerca de Odonate Therapeutics Inc

Odonate Therapeutics Inc is a Shell company. Odonate Therapeutics Inc is a Shell company.

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-

ODT Últimas noticias

Odonate Announces Expected Delisting of Its Stock

Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying Odonate that Nasdaq believes that...

Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan

Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders. This action is in...

Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash...

SHAREHOLDER ALERT: Morris Kandinov Investigating ODT, AYTU, EAR, and CORT; Shareholders are Encouraged to Contact the Firm

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Odonate Therapeutics, Inc., Aytu Biopharma...

Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021

Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three and six months ended June 30, 2021. In March 2021, Odonate announced the discontinuation of development...

Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021

Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three months ended March 31, 2021. Odonate recently announced the discontinuation of development of tesetaxel...

Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel

Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clinical data package...

Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today...

Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 S...

CONTESSA Achieved Primary Endpoint – Tesetaxel Plus a Reduced Dose of Capecitabine Significantly Improved Progression-free Survival (PFS) Versus the Approved Dose of Capecitabine Alone (Hazard...

Odonate Therapeutics Initiates Cohort 3 of CONTESSA TRIO to Evaluate Tesetaxel Monotherapy in Patients with Metastatic Breast...

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

ODT - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Odonate Therapeutics?
El precio actual de las acciones de Odonate Therapeutics es US$ 1.12
¿Cuántas acciones de Odonate Therapeutics están en circulación?
Odonate Therapeutics tiene 14,626,000 acciones en circulación
¿Cuál es la capitalización de mercado de Odonate Therapeutics?
La capitalización de mercado de Odonate Therapeutics es USD 16.38M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Odonate Therapeutics?
Odonate Therapeutics ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Odonate Therapeutics?
El ratio precio/beneficio de Odonate Therapeutics es 2.24
¿Cuál es la moneda de reporte de Odonate Therapeutics?
Odonate Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Odonate Therapeutics?
El último beneficio anual de Odonate Therapeutics es USD 7.33M
¿Cuál es la dirección registrada de Odonate Therapeutics?
La dirección registrada de Odonate Therapeutics es 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
¿Cuál es la dirección del sitio web de Odonate Therapeutics?
La dirección del sitio web de Odonate Therapeutics es www.odonate.com
¿En qué sector industrial opera Odonate Therapeutics?
Odonate Therapeutics opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
NCRANocera Inc
US$ 1.4995
(68.39%)
3.58M
MYNAMynaric AG
US$ 0.66
(50.13%)
6.68M
CREVCarbon Revolution Public Ltd
US$ 5.77
(48.33%)
196.6k
BNOXBionomics Ltd
US$ 0.3698
(46.11%)
5.95M
TIVCTivic Health Systems Inc
US$ 0.3193
(42.29%)
6.32M
FRESFresh2 Group Ltd
US$ 0.55
(-35.29%)
57.98k
SLGLSol Gel Technologies Ltd
US$ 1.19
(-27.88%)
3.41M
ANEBAnebulo Pharmaceuticals Inc
US$ 1.0201
(-18.39%)
2.65k
JZXNJiuzi Holdings Inc
US$ 1.45
(-12.12%)
312
DEVSDevvStream Corporation
US$ 0.91
(-11.65%)
124.93k
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.4364
(8.26%)
13.16M
DRCTDirect Digital Holdings Inc
US$ 6.59
(19.82%)
10.23M
MYNAMynaric AG
US$ 0.66
(50.13%)
6.68M
TIVCTivic Health Systems Inc
US$ 0.3193
(42.29%)
6.32M
BNOXBionomics Ltd
US$ 0.3698
(46.11%)
5.95M
jman4956 jman4956 5 minutos hace
Hope you have a wonderful Christmas Gus1212.
NWBO
StayHumble StayHumble 6 minutos hace
YES💹per$UBQU INSIDERS 💹Innovative Outcomes $5M Revenue+💹Growing💹 wow

https://x.com/CorporateUbqu/status/1767983893544566905?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1767983893544566905%7Ctwgr%5Efdb38bc2a31401818076d24ebd15810712ed196d%7Ctwco
UBQU
Diamondhands45 Diamondhands45 6 minutos hace
But one thing you are right about.  

Time for a break as nothing will happen for a few weeks from now anyway.

Enjoy the holiday 
SPZI
mick mick 6 minutos hace
looking good \/

NEW YORK, December 23, 2024--(BUSINESS WIRE)--Market News Alerts updates
that Litchfield Hills analyst Theodore O’Neill initiated coverage of Actelis Networks (Nasdaq:ASNS).

The firm’s price target on Actelis Networks is $5 and the firm gave Act
Asns
RichieBoy RichieBoy 6 minutos hace
How did anyone know for certain a strategic partnership was about to be an acquisition. Possible sure but if anyone already knew they were sure quiet about it. Jim could have overextended acquiring some other company. I'm relieved it's MTi if I'm being honest. Any other company would have been likel
AFFU
chereb19 chereb19 7 minutos hace
Couple of whoopers in there

You really can't be believed
RDGL
Bubae Bubae 7 minutos hace
Wow, that post triggered you? 😆 A little factual reverberation for the newbs to the board. It is rare that you see agreements with a constantly adjusting conversion price these days who's intended purpose is to move what will be much more than $1 million in new shares. In terms of stock pick
BEGI
threewheeler threewheeler 7 minutos hace
Premier Graphene Inc
@PremierGraphene
·
3m
$BIEI , El Centro, CA. President Pedro Mendez has delivered an armored vest that will be tested by Mexico's SEDENA in late January 2025, to demonstrate its efficacy for the Mexican armed forces. This further paves the way for u
BIEI
TheSprinx TheSprinx 7 minutos hace
https://allcapresearch.com/f/triple-zero-stocks-high-risk-otc-plays-with-big-gain-potential


HMBL
RealDutch RealDutch 8 minutos hace
We are all mentally exhausted and frustrated. I'm ok though because I can see the light at the end of the tunnel. And it's a very bright light. I think the same applies to Laxmi who can see more than the average employee.

And we don't need a miracle. We will get there. I also noticed
ITUP
threewheeler threewheeler 8 minutos hace
Premier Graphene Inc
@PremierGraphene
·
3m
$BIEI , El Centro, CA. President Pedro Mendez has delivered an armored vest that will be tested by Mexico's SEDENA in late January 2025, to demonstrate its efficacy for the Mexican armed forces. This further paves the way for u
BIEI
Ramazing Ramazing 8 minutos hace
Loading here
PW
TenKay TenKay 9 minutos hace
CJ plays the momo. Sometimes successfully…sometimes not.

But make no mistake. She is a trader…not an investor.

She only cares about how well the lie will hold and run the stock.

Again…sometimes successfully, sometimes not.

I LOL anytime
HMBL
threewheeler threewheeler 9 minutos hace
Premier Graphene Inc
@PremierGraphene
·
3m
$BIEI , El Centro, CA. President Pedro Mendez has delivered an armored vest that will be tested by Mexico's SEDENA in late January 2025, to demonstrate its efficacy for the Mexican armed forces. This further paves the way for u
BIEI
SSKILLZ1 SSKILLZ1 9 minutos hace
VMIR (As Of 12/23/24)

Daily Performance
Value Microcap Index:+0.80%
Value Microcap Index Rebalanced:+1.29%

Overall Performance
Value Microcap Index: +17.97%
Value Microcap Index Rebalanced:+22.96%
CHILLWILL1704 CHILLWILL1704 10 minutos hace
thats going to be the hard part unless somehow we can set up electronic signatures.
MVNT
Lime Time Lime Time 10 minutos hace
Slow buys into 2025 will take it past .01, then Sharp will bring in the meat 🚀

I'm ready for Sharp shells to have a great year. Some dollar runners
GVSI
TheSprinx TheSprinx 10 minutos hace
Duh no shard
HMBL
doomed doomed 10 minutos hace
They have no traction. BC Bud rules.
WEED
Mr. Dragon Mr. Dragon 10 minutos hace
This Friday makes FIVE weeks that Dilution Denny has sandbagged updating the share structure. What is he hiding???? MASSIVE DILUTION! Will remaining zilla cultists get their Christmas gift of massive dilution from Denny the tour guide this week?
DPLS
jimmy051357 jimmy051357 10 minutos hace
45.7 million shares today. 39.5 million @ .0001. Gettin' close, investors are starting to see something brewing, even with a R/S coming. One more week
SANP
SSKILLZ1 SSKILLZ1 10 minutos hace
VMIR (As Of 12/23/24)

Daily Performance
Value Microcap Index:+0.80%
Value Microcap Index Rebalanced:+1.29%

Overall Performance
Value Microcap Index: +17.97%
Value Microcap Index Rebalanced:+22.96%
rayovac812 rayovac812 11 minutos hace
The EMA is not real clear on this. It does say "active days" in some documents.

I suspect we find out how much of a priority their stated cost projections are, for combating AD. 210 working days isn't on an accelerated approval(AA) timeline, so this (early 2026) is close to a wor
AVXL
renaissance1 renaissance1 11 minutos hace
Agreed. But you could wake up one day sooner than you think to an approval before the expected date. At least that is what I am hoping happens. Good luck. And good post. Most likely you are spot on.
TNXP

Su Consulta Reciente

Delayed Upgrade Clock